These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
916 related articles for article (PubMed ID: 33412233)
21. Extracellular vesicles as drug delivery systems: Why and how? Elsharkasy OM; Nordin JZ; Hagey DW; de Jong OG; Schiffelers RM; Andaloussi SE; Vader P Adv Drug Deliv Rev; 2020; 159():332-343. PubMed ID: 32305351 [TBL] [Abstract][Full Text] [Related]
22. Methods for loading therapeutics into extracellular vesicles and generating extracellular vesicles mimetic-nanovesicles. Nasiri Kenari A; Cheng L; Hill AF Methods; 2020 May; 177():103-113. PubMed ID: 31917274 [TBL] [Abstract][Full Text] [Related]
23. Exploring interactions between extracellular vesicles and cells for innovative drug delivery system design. Kooijmans SAA; de Jong OG; Schiffelers RM Adv Drug Deliv Rev; 2021 Jun; 173():252-278. PubMed ID: 33798644 [TBL] [Abstract][Full Text] [Related]
24. Factors Affecting Extracellular Vesicles Based Drug Delivery Systems. Gaurav I; Thakur A; Iyaswamy A; Wang X; Chen X; Yang Z Molecules; 2021 Mar; 26(6):. PubMed ID: 33799765 [TBL] [Abstract][Full Text] [Related]
25. Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source. Meng W; He C; Hao Y; Wang L; Li L; Zhu G Drug Deliv; 2020 Dec; 27(1):585-598. PubMed ID: 32264719 [TBL] [Abstract][Full Text] [Related]
26. Extracellular Vesicle (EV) biohybrid systems for cancer therapy: Recent advances and future perspectives. Ou YH; Liang J; Czarny B; Wacker MG; Yu V; Wang JW; Pastorin G Semin Cancer Biol; 2021 Sep; 74():45-61. PubMed ID: 33609664 [TBL] [Abstract][Full Text] [Related]
27. Modulation of tissue tropism and biological activity of exosomes and other extracellular vesicles: New nanotools for cancer treatment. Kooijmans SAA; Schiffelers RM; Zarovni N; Vago R Pharmacol Res; 2016 Sep; 111():487-500. PubMed ID: 27394168 [TBL] [Abstract][Full Text] [Related]
28. The therapeutic triad of extracellular vesicles: As drug targets, as drugs, and as drug carriers. Moloudizargari M; Asghari MH; Goel A Biochem Pharmacol; 2021 Oct; 192():114714. PubMed ID: 34332957 [TBL] [Abstract][Full Text] [Related]
29. Extracellular vesicles: Mediators of microenvironment in hypoxia-associated neurological diseases. Yang H; Niu L; Jia J; Liang W; Li Q; Pan Y Clin Neurol Neurosurg; 2024 May; 240():108250. PubMed ID: 38552364 [TBL] [Abstract][Full Text] [Related]
30. Extracellular vesicles in the treatment of neurological disorders. Reed SL; Escayg A Neurobiol Dis; 2021 Sep; 157():105445. PubMed ID: 34271084 [TBL] [Abstract][Full Text] [Related]
31. Extracellular vesicles: a rising star for therapeutics and drug delivery. Du S; Guan Y; Xie A; Yan Z; Gao S; Li W; Rao L; Chen X; Chen T J Nanobiotechnology; 2023 Jul; 21(1):231. PubMed ID: 37475025 [TBL] [Abstract][Full Text] [Related]
32. Potential Roles of Extracellular Vesicles as Biomarkers and a Novel Treatment Approach in Multiple Sclerosis. Gutiérrez-Fernández M; de la Cuesta F; Tallón A; Cuesta I; Fernández-Fournier M; Laso-García F; Gómez-de Frutos MC; Díez-Tejedor E; Otero-Ortega L Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445717 [TBL] [Abstract][Full Text] [Related]
33. Engineered EVs designed to target diseases of the CNS. Nieland L; Mahjoum S; Grandell E; Breyne K; Breakefield XO J Control Release; 2023 Apr; 356():493-506. PubMed ID: 36907561 [TBL] [Abstract][Full Text] [Related]
34. Exosome-Based Macromolecular neurotherapeutic drug delivery approaches in overcoming the Blood-Brain barrier for treating brain disorders. Yadav K; Vijayalakshmi R; Kumar Sahu K; Sure P; Chahal K; Yadav R; Sucheta ; Dubey A; Jha M; Pradhan M Eur J Pharm Biopharm; 2024 Jun; 199():114298. PubMed ID: 38642716 [TBL] [Abstract][Full Text] [Related]
35. The Challenges and Possibilities of Extracellular Vesicles as Therapeutic Vehicles. Melling GE; Carollo E; Conlon R; Simpson JC; Carter DRF Eur J Pharm Biopharm; 2019 Nov; 144():50-56. PubMed ID: 31419585 [TBL] [Abstract][Full Text] [Related]
36. Cell-derived nanovesicle-mediated drug delivery to the brain: Principles and strategies for vesicle engineering. Liang Y; Iqbal Z; Lu J; Wang J; Zhang H; Chen X; Duan L; Xia J Mol Ther; 2023 May; 31(5):1207-1224. PubMed ID: 36245129 [TBL] [Abstract][Full Text] [Related]
37. Modification of Extracellular Vesicles by Fusion with Liposomes for the Design of Personalized Biogenic Drug Delivery Systems. Piffoux M; Silva AKA; Wilhelm C; Gazeau F; Tareste D ACS Nano; 2018 Jul; 12(7):6830-6842. PubMed ID: 29975503 [TBL] [Abstract][Full Text] [Related]
38. Systematic review of targeted extracellular vesicles for drug delivery - Considerations on methodological and biological heterogeneity. Gudbergsson JM; Jønsson K; Simonsen JB; Johnsen KB J Control Release; 2019 Jul; 306():108-120. PubMed ID: 31175896 [TBL] [Abstract][Full Text] [Related]
39. Extracellular vesicles through the blood-brain barrier: a review. Ramos-Zaldívar HM; Polakovicova I; Salas-Huenuleo E; Corvalán AH; Kogan MJ; Yefi CP; Andia ME Fluids Barriers CNS; 2022 Jul; 19(1):60. PubMed ID: 35879759 [TBL] [Abstract][Full Text] [Related]
40. On the Choice of the Extracellular Vesicles for Therapeutic Purposes. Campanella C; Caruso Bavisotto C; Logozzi M; Marino Gammazza A; Mizzoni D; Cappello F; Fais S Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30634425 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]